CLCellectis S.A. CLLS · NASDAQ
$0.98 +0.67% (+$0.01)
- Market cap
- $91.8M
- Enterprise value
- $140.7M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 1.6x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -41.3%
- Gross margin
- 78.3%
- Net margin
- -115.5%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 3.00
- Free float
- 85.3%
About the company
Cellectis S.A. (CLLS) is a French biotechnology company specializing in the development of immunotherapeutic drugs based on CRISPR/Cas9 cell editing technology. With a primary focus on developing therapies for cancer and genetic diseases, Cellectis is an innovative leader in the field of gene therapy. The company focuses on utilizing CRISPR/Cas9 cell editing technology to create therapeutic products that target cancer cells or correct genetic defects. Cellectis also collaborates with pharmaceutical companies on the development and commercialization of new therapeutic products. Cellectis S.A. (CLLS) shares could be suitable for investors seeking investment opportunities in biotechnology and innovative therapeutic therapies.
Sector
Healthcare
Industry
Biotechnology
CEO
Andre Choulika
Employees
229
Headquarters
Paris
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number